- Trials with a EudraCT protocol (260)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
260 result(s) found for: IPSS.
Displaying page 1 of 13.
EudraCT Number: 2006-004380-58 | Sponsor Protocol Number: A3711045 | Start Date*: 2007-03-15 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRA... | |||||||||||||
Medical condition: Lower Urinary Tract Symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) CZ (Completed) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001165-36 | Sponsor Protocol Number: FLORENCE_CC-486_HRMDS | Start Date*: 2020-10-27 | |||||||||||
Sponsor Name:Dipartimento di Medicina Sperimentale e Clinica- Università di Firenze | |||||||||||||
Full Title: A Phase 2, Monocentric, Pilot Study to evaluate safety and efficacy of CC 486 (Oral Azacitidine) Plus Best Supportive Care as maintenance of response to sc azacitidine in IPSS higher risk elderly M... | |||||||||||||
Medical condition: IPSS and IPSS-R higher Risk ( INT-2 and High risk IPSS; Intermediate, high and very high risk IPSS-R) elderly Myelodysplastic syndrome (MDS) patients | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002451-41 | Sponsor Protocol Number: NX1207-IT-CL0414 | Start Date*: 2013-08-21 | |||||||||||
Sponsor Name:Recordati S.p.A. | |||||||||||||
Full Title: EFFICACY AND SAFETY OF A SINGLE TRUS-GUIDED INTRAPROSTATIC INJECTION OF NX-1207 IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA: A PHASE III EUROPEAN CLI... | |||||||||||||
Medical condition: LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) PT (Prematurely Ended) ES (Prematurely Ended) GB (Completed) IT (Prematurely Ended) PL (Completed) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002841-21 | Sponsor Protocol Number: H6D-MC-LVHJ(a) | Start Date*: 2008-10-28 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of B... | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000848-83 | Sponsor Protocol Number: CSO181 | Start Date*: 2005-07-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Consumer Healthcare GmbH & Co KG, 77815 Bühl | |||||||||||||
Full Title: Teilverblindete, randomisierte, Placebo-kontrollierte, multizentrische Studie zur Wirksamkeit von Dickextrakt aus Kürbissamen (Kürbissamen-Extrakt) und Kürbissamen bei Patienten mit benigner Prosta... | |||||||||||||
Medical condition: benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002047-26 | Sponsor Protocol Number: FDC116115 | Start Date*: 2012-10-03 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: FDC116115: A prospective study of sexual function in sexually active men treated for BPH | ||||||||||||||||||
Medical condition: BPH (Benign prostatic hyperplasia) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GR (Completed) NL (Completed) HU (Completed) ES (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-010739-42 | Sponsor Protocol Number: H6D-MC-LVID | Start Date*: 2009-10-01 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs ... | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) BE (Completed) AT (Completed) IT (Completed) FR (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003681-27 | Sponsor Protocol Number: IDIOMEStudy | Start Date*: 2018-12-07 | |||||||||||
Sponsor Name:Groupe Francophone des Myelodysplasies | |||||||||||||
Full Title: A single-arm phase II multicenter study of IDH1 (AG 120) inhibitor in patients with IDH1 mutated myelodysplastic syndrome | |||||||||||||
Medical condition: Myelodysplastic syndrome, mutation IDH 1, inhibitor IDH-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000045-20 | Sponsor Protocol Number: KMD 3213 IT-CL 0376 | Start Date*: 2011-06-17 | |||||||||||
Sponsor Name:RECORDATI S.p.A | |||||||||||||
Full Title: Effectiveness and safety of silodosin in the treatment of LUTS in patients with benign prostatic hyperplasia: a European phase IV clinical study (the Silodosin in Real-life Evaluation study) | |||||||||||||
Medical condition: Benign prostatic hyperplasia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) PT (Completed) HU (Completed) IE (Completed) ES (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002414-38 | Sponsor Protocol Number: GEE200401 | Start Date*: 2006-01-09 |
Sponsor Name:Fundación Española de Hematología y Hemoterapia. | ||
Full Title: Estudio prospectivo, multicéntrico, abierto, de un único brazo de darbepoetin alfa en sujetos anémicos con síndrome mielodisplásico | ||
Medical condition: Tratamiento de la anemia en pacientes ³ 18 años con Síndrome Mielodisplásico (SMD) de riesgo bajo o intermedio-1 IPSS (Sistema de Puntuación de Pronóstico Internacional). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022138-10 | Sponsor Protocol Number: FI.LU.VA | Start Date*: 2010-07-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: A SINGLE-CENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION THERAPY WITH VARDENAFIL 10 mg AND TAMSULOSIN 0,4 mg IN THE TREATMENT OF MEN WITH PER... | |||||||||||||
Medical condition: men with persistent irritative urinary symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014768-21 | Sponsor Protocol Number: TUD-TEMDS1-042 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Dresden Technical University | |||||||||||||
Full Title: Treatment of MDS patients with single agent temsirolimus – a pilot study | |||||||||||||
Medical condition: Myelodysplastic Syndromes (MDS) (20 IPSS LOW+INT-1 and 20 IPSS INT-2+HIGH or proliferating CMML) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002277-38 | Sponsor Protocol Number: KMD3213ITCL0477 | Start Date*: 2015-07-30 | |||||||||||
Sponsor Name:RECORDATI S.P.A. | |||||||||||||
Full Title: Urodynamic evaluation by pressure flow urodynamic study of the new α1A-adrenoceptor antagonist silodosin 8 mg qd in patients with benign prostatic obstruction. Explorative, single-arm, phase IV cli... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002055-32 | Sponsor Protocol Number: PSD506-OAB-004 | Start Date*: 2006-10-09 | |||||||||||
Sponsor Name:Plethora Solutions Limited | |||||||||||||
Full Title: A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruct... | |||||||||||||
Medical condition: This study aims to assess the safety of PSD506 in men with benign prostatic enlargement (BPE) / benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) and an IPSS of 8-19, in li... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) IE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002598-30 | Sponsor Protocol Number: AEZS-102-036 | Start Date*: 2008-02-08 | |||||||||||
Sponsor Name:Aeterna Zentaris GmbH | |||||||||||||
Full Title: Cetrorelix pamoate in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (PBH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) FR (Completed) BG (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001693-25 | Sponsor Protocol Number: GFM-IDEALStudy | Start Date*: 2018-11-08 | |||||||||||
Sponsor Name:Groupe Francophone des Myelodysplasies | |||||||||||||
Full Title: A single-arm phase II multicenter study of IDH2 (AG 221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome | |||||||||||||
Medical condition: Myelodysplastic syndromes, mutation IDH-2, inhibitor IDH-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022111-19 | Sponsor Protocol Number: FDC114615 | Start Date*: 2010-11-22 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: Study FDC114615: Comparative efficacy of DuodartTM plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men wi... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001958-27 | Sponsor Protocol Number: H6D-MC-LVHG | Start Date*: 2006-07-13 |
Sponsor Name:Lilly ICOS LLC | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men ... | ||
Medical condition: Primary treatment of the signs and symptoms of benign prostatic hyperplasia in men (also referred to as BPH-LUTS [lower urinary tract symptoms]). BPH-LUTS include urinary frequency, urgency, interm... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) GR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016800-22 | Sponsor Protocol Number: I1A-MC-BPAE | Start Date*: 2010-05-14 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (B... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005025-25 | Sponsor Protocol Number: NIMAO/2021-1/EB-01 | Start Date*: 2022-06-08 |
Sponsor Name:CHU DE NIMES | ||
Full Title: Evaluation de l’efficacité et de la sécurité de la Tamsulosine LP 0,4mg dans le traitement de la dysurie symptomatique de la femme atteinte de sclérose en plaques. Etude contrôlée randomisée en cro... | ||
Medical condition: Patientes majeures atteintes de sclérose en plaques (EDSS < 7,5) présentant une dysurie modérée à sévère (IPSS>7) par dyssynergie vésico-sphinctérienne authentifiée au bilan urodynamique complet. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
